Preview

Онкоурология

Расширенный поиск

Сравнительный анализ о тдаленных результатов радикальной простатэктомии и дистанционной лучевой терапии у пациентов, страдающих раком предст ательной железы с высоким онкологическим риском

https://doi.org/10.17650/1726-9776-2015-11-2-61-68

Полный текст:

Аннотация

В статье представлен сравнительный анализ раковоспецифической выживаемости 202 пациентов, страдающих раком предстательной железы с высоким риском прогрессирования, которым в период с 2005 по 2008 г. была проведена дистанционная 3D-конформная лучевая терапия или радикальная простатэктомия. Методом пропорциональных рисков Кокса определены факторы, влиявшие на отдаленные результаты лечения.

Об авторе

П. Д. Демешко
ГУ «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н. Н. Александрова»; Республика Беларусь, 223040, Минский район, пос. Лесной
Россия


Список литературы

1. Океанов А. Е., Моисеев П. И., Левин Л. Ф. Статистика онкологических заболеваний в Республике Беларусь. 2003–2012 гг. Под ред. О. Г. Суконко. Минск: РНПЦ ОМР им. Н. Н. Александрова. 2013; 373 с. [Statistics of cancer diseases in the Republic of Belarus. 2003–2012. [A. E. Okeanov, P. I. Moiseev, L. F. Levin. Edited by O.G. Sukonko. Minsk: N. N. Alexandrov Research and Practical Centre of Oncology and Medical Radiology, 2013; 373 p. (In Russ.)].

2. Mohler J. L., Kantoff P. W., Armstrong A. J. et al. Prostate cancer version 2. J Natl Compr Canc Netw 2014;12(5): 686–718.

3. Grossfeld G. D., Latini D. M., Lubeck D. P. et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003;169: 157–63.

4. Yossepowitch O., Eggener S. E., Serio A. M. et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008;53:950–9.

5. Bolla М. Van Tienhoven G., Warde P. et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-years results of an EORTC randomised study. Lancet Oncol 2010;11(11):1066–73.

6. Hanks G. E., Pajak T. F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal ytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol 2003;21(21):3972–8.

7. Roach M., Bae K., Speight J. et al. Short- term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: longterm results of RTOG 8610. J Clin Oncol 2008;26(4):585–91.

8. Warde Р. Mason M., Ding K. et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378(9809):2104–11.

9. Widmark А., Klepp O., Solberg A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373(9660):301–8.

10. Shelley M. D., Kumar S., Wilt T. et al. A systematic review and meta-analysisof randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Canc Treat Rev 2009;35(1):9–17.

11. Rubin D. B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127 (8 Pt 2):757–63. 12. D , Amico A. V., Whittington R., Malkowicz S. B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.

12. Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.

13. Thompson I., Thrasher J. B., Aus G. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106–31

14. Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364(18):1708–17.

15. Wilt T. J., Brawer M. K., Jones K. M. et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367 (3):203–13.

16. Akakura K., Suzuki H., Ichikawa T. et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 2006;36:789–93.

17. Acadamies Io Mot N. Initial National Priorities for Comparative Effectiveness Research. 2009. [Cited 28 Aug 2014.]Available from URL: http://www.iom.edu/Reports/2009/ComparativeEffectivenessResearchPriorities. aspx].

18. Hoffman R. M., Koyama T., Fan K. H. et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst;2013;105:711–8.

19. Sun M., Sammon J. D., Becker A. et al. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int Published online June 20. 2013; http://dx.doi.org/10.1111/bju. 12321.

20. Aizer A. A., Yu J. B., Colberg J. W. et al. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol 2009;93:185–91.

21. Tewari A., Divine G., Chang P. et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy propensity scoring approach [published erratum appears in: J Urol 2007;177:1958]. J Urol 2007;177:911–5.

22. Nguyen P. L., Chen M. H., Catalona W. J. et al. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2009;73:659–64.

23. Zelefsky M. J., Yamada Y., Fuks Z. et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028–33.

24. Heemsbergena W. D., Al-Mamganib A., Slotc A. et al. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014;110:104–9.

25. Dearnaley D. P., Jovic G., Syndikus I. et al. Escalated dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014;15:464–73.

26. Zelefsky M. J., Fuks Z., Hunt M. et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166(3):876–81.

27. Miralbell R., Roberts S.A., Zubizaretta E. et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82(1):17–24.

28. Dasu A., Dasu I. T. Prostate alpha/beta revisited an analysis of clinical results from 14 168 patients. Acta Oncol 2012;51(8):963–74.

29. Arcangeli G., Saracino B., Gomellini S. et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78(1):11–8.

30. Prada P. J., Mendez L., Fernandez J. et al. Long-term biochemical results after highdose- rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer. Radiat Oncol 2012;7:31–9.


Для цитирования:


Демешко П.Д. Сравнительный анализ о тдаленных результатов радикальной простатэктомии и дистанционной лучевой терапии у пациентов, страдающих раком предст ательной железы с высоким онкологическим риском. Онкоурология. 2015;11(2):61-68. https://doi.org/10.17650/1726-9776-2015-11-2-61-68

For citation:


Demeshko P.D. Radical prostatectomy versus external beam radiotherapy for high risk prostate cancer: comparison of treatment outcomes. Cancer Urology. 2015;11(2):61-68. (In Russ.) https://doi.org/10.17650/1726-9776-2015-11-2-61-68

Просмотров: 682


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)